"Pharmaceutical Firms Delay Brain Tumour Research, Cancer Charity Warns"
Brain Tumour Research warns that potential new treatments for brain cancer are being hindered by pharmaceutical companies' failure to provide necessary drugs for research and regulatory delays. The charity is concerned about a reluctance to supply costly drugs for research due to brain cancer being a rare condition. Campaigners are pushing for new regulations to fast-track drug approvals and require pharmaceutical firms to provide drugs for trials, citing the lack of progress in treatment for 30 years and underfunding of research.